Viatris Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Viatris Inc trades at $17.35 (market cap $20.03B), while Consumer Staples Select Sector SPDR Fund trades at $83.31 (market cap $13.50B). The key difference: Viatris Inc is the larger of the two by market cap, and Viatris Inc pays a 2.75% dividend while Consumer Staples Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Viatris Inc for 57 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| VTRS | XLP | |
|---|---|---|
Market Cap | $20.03B | $13.50B |
Volume | 14,109,977 | 14,599,953 |
Sector | Health | — |
52-Week High | $18.27 | $90.00 |
52-Week Low | $9.74 | $75.61 |
Typical Hold Time | 57 Days | 72 Days |
Enterprise Value | $32.15B | — |
Dividend Yield | 2.75% | — |
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
XLP (Consumer Staples Select Sector SPDR ETF) trades at $83.21, up 1.85% with bullish technical signals from moving averages and oscillators. The ETF has gained 6.6% year-to-date, outperforming consumer discretionary stocks. Analyst consensus is strongly positive with 100% buy ratings. Recent news highlights XLP's defensive characteristics amid economic uncertainty and its competitive expense ratio advantage over peers.
The outlook remains favorable given XLP's defensive positioning in consumer staples, though rising interest rates pose a headwind. Investment opportunity lies in the ETF's stability during market volatility, while risks include persistent inflation pressures and potential consumer spending slowdown. The technical setup suggests continued upward momentum with support at $82-83 levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →